Given the powerful and diverse role of CLRs in modulating innate and adaptive immune responses in IBD and CAC, such as the role of Dectin-1 in Treg amplification and the role of DC-SIGN in tumor metastasis, CLRs is undoubtedly very promising and worth-exploring therapeutic targets. The gene discussed is LARS1; the disease is inflammatory bowel disease.